Fasenra (benralizumab) is a prescription drug that’s used to treat conditions such as eosinophilic asthma. Fasenra is given as an injection under your skin. This drug should not be used in certain ...
FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca ...
Dr. Michael Wechsler, Professor of Medicine and Director of The Asthma Institute at National Jewish Health, and International Coordinating Investigator of the MANDARA trial said: “This approval is ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced results from the Phase III extension BORA trial evaluating the long-term safety and efficacy of FASENRA™ (benralizumab) as an add-on ...
The FDA has expanded the approval of Fasenra (benralizumab; AstraZeneca) to include self-administration with the Fasenra Pen, a prefilled, single-use autoinjector. The Food and Drug Administration ...
Fasenra receives positive EU CHMP opinion for self-administrationand the new Fasenra pen, a pre-filled, single-use auto-injector AstraZeneca today announced that the European Medicines Agency's ...
AstraZeneca, global, science-led biopharmaceutical company, announced that its Fasenra (benralizumab) has been recommended for approval in the European Union (EU) as an add-on treatment for adult ...
Positive high-level results from the MANDARA phase III trial showed AstraZeneca’s Fasenra (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results